Dr. Riess on the Long-Term Benefit With Immunotherapy for Lung Cancer

Jonathan Riess, MD
Published: Friday, Sep 01, 2017



Jonathan Riess, MD, assistant professor of medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses the long-term benefit with immunotherapy for patients with lung cancer.

According to Riess, patients with stage IV non


Jonathan Riess, MD, assistant professor of medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses the long-term benefit with immunotherapy for patients with lung cancer.

According to Riess, patients with stage IV non

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging Liquid Biopsies in Tumor Characterization for NSCLC TherapyJan 31, 20181.5
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Publication Bottom Border
Border Publication
x